Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to lucentis therapy

Retina

Volumn 29, Issue 7, 2009, Pages 1013-1018

  Das, Radha ^a   Shi, Yanyun ^b   Silvestri, Guiliana ^a   Chakravarthy, Usha ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Shanxi Eye Hospital   (China)

Author keywords

Optical coherence tomography; Preferential hyperacuity perimetry; Ranibizumab; Visual function

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT MONITORING; PERIMETRY; PREFERENTIAL HYPERACUITY PERIMETRY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SUBRETINAL FLUID; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL FIELD DEFECT;

EID: 68249098931     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181a91dbf     Document Type: Article

References (19)

1. Doris N, Hart PM, Chakravarthy U, et al. Relation between macular morphology and visual function in patients with choroidal neovascularisation of age-related macular degeneration. Br J Ophthalmol 2001;85:184-188. (Pubitemid 32146758)
2. Hogg R, Stevenson MR, Winder J, McClure M, Chakravarthy U. Macular lesion composition and location influence visual function in AMD. Br J Ophthalmol 2003;87:609-614.
3. Querques G, Bux AV, Prato R, Iaculli C, Souied EH, Delle Noci N. Correlation of visual function impairment and optical coherence tomography findings in patients with adult-onset foveomacular vitelliform macular dystrophy. Am J Ophthalmol 2008;146:135-142.
4. Chakravarthy U, Walsh AC, Muldrew A, Updike PG, Barbour T, Sadda SR. Quantitative fluorescein angiographic analysis of choroidal neovascular membranes: validation and correlation with visual function. Invest Ophthalmol Vis Sci 2007;48:349-354. (Pubitemid 47251423)
5. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol 2008;92:361-364.
6. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536. (Pubitemid 46282944)
7. Krebs I, Binder S, Stolba U, et al. Optical coherence tomography guided retreatment of photodynamic therapy. Br J Ophthalmol 2005;89:1184-1187. (Pubitemid 41224472)
8. Fletcher DC, Schuchard RA. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Optom Vis Sci 2006;83:178-189.
9. McClure M, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000;84:244-250.
10. Mones J, Rubin GS. Contrast sensitivity as an outcome measure in subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye 2005;19:1142-1150.
11. Mitchell J, Wolffsohn J, Woodcock A, et al. The MacDQoL individualized measure of the impact of macular degeneration on quality of life: reliability and responsiveness. Am J Ophthalmol 2008;146:447-454.
12. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
13. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-11144
14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
15. Alster Y, Bressler NM, Bressler SB, et al; Preferential Hyperacuity Perimetry Research Group. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology 2005;112:1758-1765.
16. Goldstein M, Loewenstein A, Barak A, et al; Preferential Hyperacuity Perimeter Research Group. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005;25:296-303.
17. Trevino R. Recent progress in macular function self assessment. Ophthalmic Physiol Opt 2008;28:183-192. (Pubitemid 351569418)
18. Wylegala EA, Pilat J, Teper SJ, Wroblewska-Czajka E, Bartusek M. Monitoring of photodynamic therapy results in age-related macular degeneration by means of preferential hyperacuity perimeter. Eur J Ophthalmol 2007;17:768-775.
19. Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 2008;115:e39-e46.